NBI-1117568-SCZ3030: Evaluation of NBI-1117568 in Inpatient Adults With Schizophrenia
Start Date
8/11/2025
Completion Date
11/1/2027
Summary
The primary objective for this study is to evaluate the efficacy of NBI-1117568 compared with placebo on improving behavioral and psychological symptoms of schizophrenia in adults.
Eligibility Criteria
Age Range: 18 years to 65 years
Interventions
NBI-1117568
Placebo
Conditions
Locations
Neurocrine Clinical Site
Little Rock, Arkansas 72211
United States
Neurocrine Clinical Site
Culver City, California 90230
United States
Neurocrine Clinical Site
Garden Grove, California 92845
United States
Neurocrine Clinical Site
Riverside, California 92506
United States
Neurocrine Clinical Site
Hollywood, Florida 33024
United States
Neurocrine Clinical Site
Atlanta, Georgia 30328
United States
Neurocrine Clinical Site
North Canton, Ohio 44720
United States
Neurocrine Clinical Site
Pleven, 5802
Bulgaria
Neurocrine Clinical Site
Sliven, 8800
Bulgaria
Neurocrine Clinical Site
Veliko Tarnovo, 5047
Bulgaria
Neurocrine Clinical Site
Vratsa, 3001
Bulgaria
Neurocrine Clinical Site
Budapest, 1083
Hungary
Neurocrine Clinical Site
Gyöngyös, 3200
Hungary
Neurocrine Clinical Site
Győr, 9024
Hungary
Neurocrine Clinical Site
Brasov, 500123
Romania
Neurocrine Clinical Site
Brasov, 507190
Romania
Neurocrine Clinical Site
Bucharest, 41914
Romania
Neurocrine Clinical Site
Belgrade, 11000
Serbia
Neurocrine Clinical Site
Gornja Toponica, 18202
Serbia
Neurocrine Clinical Site
Kragujevac, 34000
Serbia